Abbott Laboratories (NYSE:ABT) insider Alejandro D. Wellisch sold 2,153 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares of the company’s stock, valued at $572,900.16. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Abbott Laboratories (NYSE:ABT) traded up $0.33 on Friday, reaching $56.13. 2,148,282 shares of the company’s stock were exchanged, compared to its average volume of 6,619,619. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a twelve month low of $37.38 and a twelve month high of $56.69. The stock has a market cap of $97,125.53, a price-to-earnings ratio of 23.15, a P/E/G ratio of 2.09 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same period last year, the firm posted $0.59 EPS. The company’s revenue was up 28.8% on a year-over-year basis. equities research analysts expect that Abbott Laboratories will post 2.49 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th were issued a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 83.47%.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/24/alejandro-d-wellisch-sells-2153-shares-of-abbott-laboratories-abt-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Heritage Trust Co grew its holdings in shares of Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after purchasing an additional 200 shares in the last quarter. Tributary Capital Management LLC purchased a new position in shares of Abbott Laboratories in the third quarter valued at $106,000. Winfield Associates Inc. grew its holdings in shares of Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after purchasing an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. grew its holdings in shares of Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after purchasing an additional 370 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after purchasing an additional 2,094 shares in the last quarter. 69.99% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently issued reports on ABT shares. BidaskClub lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a report on Thursday, August 3rd. Cowen Inc reissued a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a report on Thursday, August 17th. Finally, Citigroup Inc. started coverage on shares of Abbott Laboratories in a report on Thursday, August 17th. They issued a “neutral” rating and a $53.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus price target of $56.81.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.